ISPOR 2019 (US)

May 18 - May 22, 2019

New Orleans, LA | New Orleans Ernest N. Morial Convention Center |

Eliminating Barriers to Access on the Drug Commercialization Journey 

Optimal reimbursement, target market access, and pricing are critical challenges for manufacturers as they seek to achieve acceptable levels of return on investment after lengthy and costly development programs. The evidence requirements of payers has yet to be routinely integrated into clinical and regulatory planning. The consequence is noteworthy as many new health treatments fail to achieve their commercial potential.

PAREXEL offers a resourceful solution for commercialization by aligning evidence generation and economic evaluation with pricing, reimbursement, and strategy-driven market access consulting.                   

 Visit ISPOR US to view the full agenda and register to attend.

REGISTER

Presentations

Podium Presentation:
TBD   
IMPROVING PATIENT ACCESS TO LIFE-SAVING THERAPIES: WHAT NEEDS TO BEDONE TO FULFILL THE PROMISE OF BIOSIMILARS 

Jackie Vanderpuye-Orgle, Senior Director, Health Economics

Advanced Workshop
Tuesday May 21
11:00 AM – 12:00 PM   
HOW TO TACKLE THE ESTIMATION OF TREATMENT IMPACT IN THE PRESENCE OF DIFFERENTIAL WITHDRAWAL AND MISSING DATA AMOUNG STUDY ARMS?
Helene Karcher, VP Health Economics Modelling and Simulation

Issue Panel:
Tuesday May 21
2:15 –3:15
HOW CAN NEW OUTCOMES SUCH AS THE ONES DERIVED FROM WEARABLES OR PATIENT EXPERIENCE REPORTS BE USEFUL IN REIMBURSEMENT AND COVERAGE DECISIONS
Speakers:
Katja Rudell, Director, Clinical Outcomes Assessment Helene
Karcher, VP Health Economics Modelling and Simulation

View all our posters & presentations

Can't make it to ISPOR's 2019 US Congress?  
Click here to access valuable content and expert insights to help you on your journey to market success.

We are always available for a conversation.

*